Trend·igger

moderna stock

Search on Google

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

Trending in 24 countries: …

Peak volume

1K+

First seen

2026-08-19

Last seen

2026-08-19

Days trending

1 / 1

Countries

24

Trending timeline

1000+

Latest related news (2026-08-19)

Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90% — CNBC
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial — STAT
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melano — Business Wire